Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
PCSA similar filings
- 25 Jan 24 NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
- 19 Jan 24 Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
- 18 Jan 24 Material Modifications to Rights of Security Holders
- 8 Jan 24 Regulation FD Disclosure
- 19 Dec 23 FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
- 5 Dec 23 Regulation FD Disclosure
- 16 Nov 23 Regulation FD Disclosure
Filing view
External links